% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • toowan12 toowan12 Nov 16, 2012 9:22 AM Flag

    The theat is not generic but a new drug

    U talkin Sapacitabine? If so, u would be correct.phase II/III meeting endpoints for elderly aml/mds. the bright side is that there is a strong possibility for combination (Dac & Sap) therapy.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Sapacitabine the ph2 and 300 pts, took almost 4 years...max would have a heart attack on that one. They now have combined it with dacogen. Maybe it needed a little help? The ph3 will finish in Apr 2015.

      Responses that I could find in 200MG 63 pts 1 CR 2 Improved blood counts

      Survival under 290 days

      We'll have to see.

      Rory a few years ago was touting Revlmid as a threat. Never materialized except in mild mds.

      SGI-110 only needed 14 pts in MDS in the ph2 and taking less than a year? Compared to 4 years for sapacitabine. I would like astx to cross over the ph2 into the ph3. Shaving off year on data.

      Sentiment: Strong Buy